What is the appropriate management of an acute COPD exacerbation?

Management of Acute COPD Exacerbation

Immediately initiate combined short-acting bronchodilators (salbutamol 2.5–5 mg plus ipratropium 0.25–0.5 mg via nebulizer every 4–6 hours), oral prednisone 30–40 mg daily for exactly 5 days, controlled oxygen targeting SpO₂ 88–92%, and antibiotics for 5–7 days when sputum purulence is present with either increased dyspnea or sputum volume. 1

Immediate Pharmacological Management

Bronchodilator Therapy

• Administer combined nebulized salbutamol 2.5–5 mg plus ipratropium 0.25–0.5 mg every 4–6 hours during the acute phase, as this combination provides superior bronchodilation lasting 4–6 hours compared with either agent alone. 1
• Nebulizers are preferred over metered-dose inhalers in hospitalized patients with severe exacerbations because they eliminate the need for coordinated high-frequency inhalations and are easier for dyspneic patients to use. 1
• Power nebulizers with compressed air (not oxygen) when hypercapnia or respiratory acidosis is present, delivering supplemental oxygen separately via nasal cannula at 1–2 L/min. 1
• Continue scheduled nebulized bronchodilators every 4–6 hours until clinical improvement occurs, typically within 24–48 hours, then transition to a metered-dose inhaler with spacer. 1
• Never use intravenous methylxanthines (theophylline/aminophylline) as they increase adverse effects without clinical benefit. 1

Systemic Corticosteroid Protocol

• Give oral prednisone 30–40 mg once daily for exactly 5 days starting immediately; this short course is as effective as a 14-day regimen while reducing cumulative steroid exposure by more than 50%. 1
• Oral administration is equally effective to intravenous and should be the default route unless the patient cannot tolerate oral intake. 1
• This 5-day regimen improves lung function and oxygenation, shortens recovery time and hospital stay, reduces treatment failure by over 50%, and lowers 30-day rehospitalization risk. 1
• Do not extend systemic corticosteroids beyond 5–7 days for a single exacerbation unless another indication exists, as longer courses increase adverse effects without added benefit. 1

Antibiotic Therapy

• Prescribe antibiotics for 5–7 days when sputum purulence is present together with either increased dyspnea or increased sputum volume (two of three cardinal symptoms, with purulence required). 1
• This strategy reduces short-term mortality by approximately 77%, treatment failure by 53%, and sputum purulence by 44%. 1
• First-line oral agents include amoxicillin-clavulanate 875/125 mg twice daily, doxycycline 100 mg twice daily, or azithromycin (500 mg day 1, then 250 mg daily for 4 days), selected according to local resistance patterns. 1
• The most common causative organisms are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. 1
• Do not prescribe antibiotics routinely; limit use to cases meeting the purulent-sputum plus another cardinal symptom criteria. 1

Oxygen Management and Monitoring

Controlled Oxygen Delivery

• Target SpO₂ of 88–92% using controlled-delivery devices (Venturi mask 24–28% FiO₂ or nasal cannula 1–2 L/min) to correct life-threatening hypoxemia while minimizing CO₂ retention and respiratory acidosis. 1
• High-flow oxygen (>28% FiO₂ or >4 L/min) delivered without concurrent blood-gas monitoring worsens hypercapnic respiratory failure and increases mortality by approximately 78%. 1

Arterial Blood Gas Monitoring

• Obtain an arterial blood gas within 60 minutes of initiating oxygen to identify hypercapnia (PaCO₂ > 45 mmHg) or acidosis (pH < 7.35). 1
• If the patient deteriorates clinically or the initial pH is < 7.35, repeat the arterial blood gas 30–60 minutes later. 1
• When the initial ABG shows normal pH and PaCO₂, the saturation target may be increased to 94–98% only if the patient has no prior hypercapnic failure requiring NIV and their usual stable saturation is ≥94%. 1

Non-Invasive Ventilation (NIV)

• Initiate NIV immediately as first-line therapy when acute hypercapnic respiratory failure (PaCO₂ > 45 mmHg) with acidosis (pH < 7.35) persists for more than 30 minutes after standard medical treatment. 1
• Specific indications include pH < 7.35 with PaCO₂ > 45 mmHg persisting >30 minutes and a respiratory rate ≥25–30 breaths/min. 1
• NIV improves gas exchange, reduces work of breathing, decreases intubation rates by approximately 50%, shortens hospital stay, and improves survival; success rates in appropriately selected patients are 80–85%. 1, 2
• Transfer to ICU if pH remains <7.26 despite NIV. 1
• Contraindications to NIV include inability to protect the airway, large-volume secretions, hemodynamic instability, or recent facial/upper-airway surgery. 1

Hospitalization Criteria

Admit or evaluate in the emergency department if any of the following are present: 1

• Marked increase in dyspnea unresponsive to outpatient therapy
• Respiratory rate >30 breaths/min
• Inability to eat or sleep because of respiratory symptoms
• New or worsening hypoxemia (SpO₂ <90% on room air)
• New or worsening hypercapnia (PaCO₂ >45 mmHg)
• Altered mental status or loss of alertness
• High-risk comorbidities (pneumonia, cardiac arrhythmia, heart failure, diabetes, renal or liver failure)
• Inability to care for self at home
• Persistent rhonchi after initial treatment requiring continued nebulization

Severity Classification for Treatment Setting

• Mild exacerbations are managed outpatient with short-acting bronchodilators alone. 1
• Moderate exacerbations require outpatient bronchodilators plus antibiotics and/or oral corticosteroids. 1
• Severe exacerbations necessitate hospital or emergency-department care, often with acute respiratory failure. 1

Discharge Planning and Follow-Up

Pulmonary Rehabilitation

• Schedule pulmonary rehabilitation within 3 weeks after discharge to reduce hospital readmissions and improve quality of life. 1
• Do not initiate pulmonary rehabilitation during hospitalization, as this increases mortality; wait until post-discharge. 1

Maintenance Therapy Optimization

• Optimize long-acting bronchodilator therapy (LAMA, LABA, or combinations) before discharge. 1
• Do not step down from triple therapy (LAMA + LABA + ICS) during or immediately after an exacerbation, as inhaled corticosteroid withdrawal raises the risk of recurrent exacerbations. 1
• Verify proper inhaler technique with the patient at discharge. 1

Preventive Measures

• Provide smoking cessation counseling with nicotine replacement therapy and behavioral support for current smokers. 1
• Schedule a follow-up visit within 3–7 days to assess treatment response and prevent subsequent exacerbations. 1

Common Pitfalls to Avoid

• Never power nebulizers with oxygen in hypercapnic patients; use compressed air and provide supplemental oxygen via a separate nasal cannula. 1
• Never delay NIV when criteria for acute hypercapnic respiratory failure are met (pH < 7.35, PaCO₂ > 45 mmHg persisting >30 minutes). 1
• Never use methylxanthines (theophylline/aminophylline) in acute exacerbations—they add toxicity without benefit. 1
• Never continue systemic corticosteroids beyond 5–7 days for a single exacerbation unless another indication exists. 1
• Never administer high-flow oxygen without arterial blood-gas monitoring, as this can worsen hypercapnic respiratory failure and increase mortality. 1
• Do not use chest physiotherapy in acute COPD exacerbations, as there is no evidence of benefit. 1
• Diuretics are indicated only when peripheral edema and elevated jugular venous pressure are present; avoid aggressive diuresis that could compromise cardiac output. 1